Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib
together with erlotinib may kill more tumor cells.
PURPOSE: This phase II trial is studying the best dose of erlotinib when given together with
sunitinib and to see how well they work in treating patients with unresectable or metastatic
kidney cancer.